Search research articles
Contact Us
Filters
Showing results (241-250 of 299) with videos related to
Page
of 30
Sort By:
European Heart Journal
|
August 8, 2007
Randomized, double-blind, placebo-controlled study to evaluate the effect of two dosing regimens of darbepoetin alfa in patients with heart failure and anaemia
Dirk J van Veldhuisen, Kenneth Dickstein, Alain Cohen-Solal, et al.
Journal of Cell Science
|
January 28, 2014
The role of Hath6, a newly identified shear-stress-responsive transcription factor, in endothelial cell differentiation and function
Fang Fang, Scott M Wasserman, Jesus Torres-Vazquez, et al.
Alcohol, Clinical & Experimental Research
|
October 21, 2023
Effectiveness of contingency management using transdermal alcohol monitoring to reduce heavy drinking among driving while intoxicated (DWI) arrestees: A randomized controlled trial
Donald M Dougherty, Tae-Joon Moon, Yuanyuan Liang, et al.
Journal of Cardiovascular Pharmacology and Therapeutics
|
May 18, 2018
Comparison of LDL-C Reduction Using Different Evolocumab Doses and Intervals: Biological Insights and Treatment Implications
Scott M Wasserman, Marc S Sabatine, Michael J Koren, et al.
Journal of the American College of Cardiology
|
October 26, 2019
Long-Term Efficacy and Safety of Evolocumab in Patients With Hypercholesterolemia
Michael J Koren, Marc S Sabatine, Robert P Giugliano, et al.
Diabetes, Obesity & Metabolism
|
September 14, 2016
Evaluation of the efficacy, safety and glycaemic effects of evolocumab (AMG 145) in hypercholesterolaemic patients stratified by glycaemic status and metabolic syndrome
Dirk J Blom, Michael J Koren, Eli Roth, et al.
The Pediatric Infectious Disease Journal
|
June 1, 1993
Antimicrobial treatment of occult bacteremia: a multicenter cooperative study
J W Bass, R W Steele, R R Wittler, et al.
Clinical Cardiology
|
June 21, 2012
Design and rationale of the LAPLACE-TIMI 57 trial: a phase II, double-blind, placebo-controlled study of the efficacy and tolerability of a monoclonal antibody inhibitor of PCSK9 in subjects with hypercholesterolemia on background statin therapy
Payal Kohli, Nihar R Desai, Robert P Giugliano, et al.
JAMA Cardiology
|
December 13, 2018
Interindividual Variation in Low-Density Lipoprotein Cholesterol Level Reduction With Evolocumab: An Analysis of FOURIER Trial Data
Arman Qamar, Robert P Giugliano, Anthony C Keech, et al.
JAMA
|
May 15, 2014
Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial
Jennifer G Robinson, Bettina S Nedergaard, William J Rogers, et al.
Page
of 30
Search research articles
Search
Showing results (241-250 of 299) with videos related to
Sort By:
Page
of 30
European Heart Journal
|
August 8, 2007
Randomized, double-blind, placebo-controlled study to evaluate the effect of two dosing regimens of darbepoetin alfa in patients with heart failure and anaemia
Dirk J van Veldhuisen, Kenneth Dickstein, Alain Cohen-Solal, et al.
Journal of Cell Science
|
January 28, 2014
The role of Hath6, a newly identified shear-stress-responsive transcription factor, in endothelial cell differentiation and function
Fang Fang, Scott M Wasserman, Jesus Torres-Vazquez, et al.
Alcohol, Clinical & Experimental Research
|
October 21, 2023
Effectiveness of contingency management using transdermal alcohol monitoring to reduce heavy drinking among driving while intoxicated (DWI) arrestees: A randomized controlled trial
Donald M Dougherty, Tae-Joon Moon, Yuanyuan Liang, et al.
Journal of Cardiovascular Pharmacology and Therapeutics
|
May 18, 2018
Comparison of LDL-C Reduction Using Different Evolocumab Doses and Intervals: Biological Insights and Treatment Implications
Scott M Wasserman, Marc S Sabatine, Michael J Koren, et al.
Journal of the American College of Cardiology
|
October 26, 2019
Long-Term Efficacy and Safety of Evolocumab in Patients With Hypercholesterolemia
Michael J Koren, Marc S Sabatine, Robert P Giugliano, et al.
Diabetes, Obesity & Metabolism
|
September 14, 2016
Evaluation of the efficacy, safety and glycaemic effects of evolocumab (AMG 145) in hypercholesterolaemic patients stratified by glycaemic status and metabolic syndrome
Dirk J Blom, Michael J Koren, Eli Roth, et al.
The Pediatric Infectious Disease Journal
|
June 1, 1993
Antimicrobial treatment of occult bacteremia: a multicenter cooperative study
J W Bass, R W Steele, R R Wittler, et al.
Clinical Cardiology
|
June 21, 2012
Design and rationale of the LAPLACE-TIMI 57 trial: a phase II, double-blind, placebo-controlled study of the efficacy and tolerability of a monoclonal antibody inhibitor of PCSK9 in subjects with hypercholesterolemia on background statin therapy
Payal Kohli, Nihar R Desai, Robert P Giugliano, et al.
JAMA Cardiology
|
December 13, 2018
Interindividual Variation in Low-Density Lipoprotein Cholesterol Level Reduction With Evolocumab: An Analysis of FOURIER Trial Data
Arman Qamar, Robert P Giugliano, Anthony C Keech, et al.
JAMA
|
May 15, 2014
Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial
Jennifer G Robinson, Bettina S Nedergaard, William J Rogers, et al.
Page
of 30